Datum Orthobiologics has been founded and is raising funds to develop bio-programmable biomaterials with musculoskeletal applications. The company will first focus on bone grafts for use in fracture healing and spinal fusion.
Datum Orthobiologics benefits from patented GLYMATRIX® technology, which is based on 25+ years of R&D and postmarketing research as well as intellectual property acquired from Johnson & Johnson.
GLYMATRIX was first used in dental and aesthetic applications. The technology derives from sugars that crosslink collagen molecules to produce matrices that can be tailored for longevity, degradation rates, etc. Commercially, the technology has been used in over half a million procedures.
Datum Orthobiologics has been founded and is raising funds to develop bio-programmable biomaterials with musculoskeletal applications. The company will first focus on bone grafts for use in fracture healing and spinal fusion.
Datum Orthobiologics benefits from patented GLYMATRIX® technology, which is based on 25+ years of R&D and...
Datum Orthobiologics has been founded and is raising funds to develop bio-programmable biomaterials with musculoskeletal applications. The company will first focus on bone grafts for use in fracture healing and spinal fusion.
Datum Orthobiologics benefits from patented GLYMATRIX® technology, which is based on 25+ years of R&D and postmarketing research as well as intellectual property acquired from Johnson & Johnson.
GLYMATRIX was first used in dental and aesthetic applications. The technology derives from sugars that crosslink collagen molecules to produce matrices that can be tailored for longevity, degradation rates, etc. Commercially, the technology has been used in over half a million procedures.
Copy to clipboard 
